Neogenomics Inc (NEO): Maher Albitar , Chief Medical Officer of Neogenomics Inc sold 105,300 shares on Sep 20, 2016. The Insider selling transaction was reported by the company on Sep 22, 2016 to the Securities and Exchange Commission. The shares were sold at $8.20 per share for a total value of $863,460.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Sep 13, 2016, Maher Albitar (Chief Medical Officer) sold 60,075 shares at $8.26 per share price.On May 27, 2016, Oort Douglas M Van (Chairman and CEO) sold 481,387 shares at $8.72 per share price.Also, On May 20, 2016, Steven A Ross (CIO) sold 18,000 shares at $8.50 per share price.On May 3, 2016, Steven C Jones (Executive VP of Finance) sold 177,745 shares at $8.21 per share price.
NeoGenomics: On Tuesday, Sep 21, 2016 heightened volatility was witnessed in NeoGenomics which led to swings in the share price. The shares opened for trading at $8.14 and hit $8.245 on the upside , eventually ending the session at $8.22, with a gain of 1.23% or 0.1 points. The heightened volatility saw the trading volume jump to 2,96,295 shares. The 52-week high of the share price is $9.54 and the company has a market cap of $640 M . The 52-week low of the share price is at $5.49.
Company has been under the radar of several Street Analysts.NeoGenomics is Reiterated by The Benchmark Company to Buy and the brokerage firm has raised the Price Target to $ 12 from a previous price target of $10 .The Rating was issued on Jul 27, 2016.
NeoGenomics Inc. is an operator of a network of cancer-focused genetic testing laboratories. The Company offers testing services which includes Cytogenetics testing which is the study of normal and abnormal chromosomes and their relationship to disease; fluorescence in-situ hybridization (FISH) testing which is a branch of cancer genetics that focuses on detecting and locating the presence or absence of specific deoxyribonucleic acid (DNA) sequences and genes on chromosomes; flow cytometry testing which is a way to measure the characteristics of cell populations; immunohistochemistry (IHC) testing which is a process of identifying cell proteins in a tissue section utilizing the principle of antibodies binding specifically to in biological tissues. and molecular testing which is a cancer diagnostic tool focusing on the analysis of DNA and ribonucleic acid (RNA) as well as the structure and function of genes at a molecular level.